Vireo Growth (VREOF) Free Cash Flow Growth (1y) (2021 - 2026)
Vireo Growth (VREOF) Free Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.45 Bn | 29.77 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.23 Bn | 19.57 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.47 Bn | 15.08 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.70 Bn | 11.17 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Vireo Growth | 489.19 Mn | 346.89 Mn | 95.30 Mn | -1,144.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 124.44% |
| Dec 31, 2025 | 195.96% |
| Sep 30, 2025 | -173.49% |
| Jun 30, 2025 | -164.33% |
| Mar 31, 2025 | -115.35% |
| Dec 31, 2024 | -228.21% |
| Sep 30, 2024 | -597.52% |
| Jun 30, 2024 | -394.23% |
| Mar 31, 2024 | 47.67% |
| Dec 31, 2023 | 58.59% |
| Sep 30, 2023 | 148.06% |
| Jun 30, 2023 | 86.60% |
| Mar 31, 2023 | 55.31% |
| Dec 31, 2022 | 39.82% |
| Sep 30, 2022 | 64.62% |
| Jun 30, 2022 | 74.06% |
| Mar 31, 2022 | 9.73% |
| Dec 31, 2021 | -133.18% |
| Sep 30, 2021 | -55.47% |
| Jun 30, 2021 | -229.50% |